Patents by Inventor Jari Helin
Jari Helin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170189549Abstract: The present invention relates to a conjugate represented by the formula [D-L-Y—(CH2)n-O]m—P-T wherein T is a protein; P is a polymer selected from the group consisting of dextran, mannan, pullulan, hyaluronic acid, hydroxyethyl starch, chondroitin sulphate, heparin, heparin sulphate, polyalkylene glycol, Ficoll, polyvinyl alcohol, amylose, amylopectin, chitosan, cyclodextrin, pectin and carrageenan, or a derivative thereof; m is at least 1; n is in the range of 1 to 10; each Y is independently selected from the group consisting of S, NH and 1,2,3-triazolyl, wherein 1,2,3-triazolyl is optionally substituted; each L is independently absent or comprises a linker group covalently joining D and Y; and each D is a payload molecule.Type: ApplicationFiled: June 12, 2015Publication date: July 6, 2017Applicant: Glykos Finland OyInventors: Jari Helin, Juhani Saarinen, Filip S. Ekholm, Anne Leppanen
-
Publication number: 20170112931Abstract: The present invention relates to a conjugate comprising an anti-EGFR1 antibody or an EGFR binding fragment thereof and at least one dextran derivative, wherein the dextran derivative comprises at least one D-glucopyranosyl unit, wherein at least one carbon selected from carbon 2, 3 or 4 of the at least one D-glucopyranosyl unit is substituted by a substituent of the formula —O—(CH2)n—S—B12H112? wherein n is in the range of 3 to 10; and the dextran derivative is bound to the anti-EGFR antibody or an EGFR1 binding fragment thereof via a bond formed by a reaction between at least one aldehyde group formed by oxidative cleavage of a D-glucopyranosyl unit of the dextran derivative and an amino group of the anti-EGFR1 antibody or an EGFR1 binding fragment thereof.Type: ApplicationFiled: June 12, 2015Publication date: April 27, 2017Applicant: Tenboron OyInventors: Anne Leppanen, Filip S. Ekholm, Jari Helin, Hanna Salo, Anne Kanerva
-
Publication number: 20170002095Abstract: The present invention describes glycans, which are specifically expressed by certain cancer cells, tumours and other malignant tissues. The present invention describes methods to detect cancer specific glycans as well as methods for the production of reagents binding to said glycans. The invention is also directed to the use of said glycans and reagents binding to them for the diagnostics of cancer and malignancies. Furthermore, the invention is directed to the use of said glycans and reagents binding to them for the treatment of cancer and malignancies. Moreover, the present invention comprises efficient methods to differentiate between malignant and benign tumors by analyzing glycan structures.Type: ApplicationFiled: September 14, 2016Publication date: January 5, 2017Applicant: Glykos Finland OyInventors: Tero SATOMAA, Jari NATUNEN, Annamari HEISKANEN, Anne OLONEN, Juhani SAARINEN, Noora SALOVUORI, Jari HELIN
-
Publication number: 20160151485Abstract: Objective of the present invention is to provide polysaccharides which modulate immune response, and which can be used as ingredients in edible products or pharmaceutical compositions. The present invention provides such polysaccharides obtained from the species Camellia sinensis, which comprise a rhamnogalacturonan-I core, and wherein the molar ratio of galacturonyl acid residues to rhamnosyl residues in the backbone of the polysaccharide is close to 1:1. The present invention also provides edible products or pharmaceutical compositions containing such polysaccharides, in order to modulate immune response.Type: ApplicationFiled: February 8, 2016Publication date: June 2, 2016Applicant: NutriLeads B.V.Inventors: Ruud ALBERS, Jari HELIN, Werner KLAFFKE, Jean Hypolites KOEK, Petronella Anna KREIJVELD, Jari NATUNEN, Erwin Werner TAREILUS, Richardus Paulus Anton ORANJE
-
Patent number: 9320291Abstract: The present invention is directed to a method of production of an immunostimulatory composition having a saccharide fraction, the method including the steps of hydrolyzes of yeast cells and recovering the soluble fraction. The saccharide fraction having composition thus obtained may be incorporated as a food or beverage component or be used as a pharmaceutical for treatment of specific conditions.Type: GrantFiled: December 18, 2009Date of Patent: April 26, 2016Assignee: GLYKOS FINLAND OYInventors: Juhani Saarinen, Ritva Niemela, Jari Helin, Jari Natunen, Jukka Hiltunen
-
Publication number: 20160106860Abstract: The invention relates to a glycoprotein-toxic payload molecule conjugate, a toxic payload molecule-glycan conjugate, and a pharmaceutical composition. The invention further relates to a method for preparing the glycoprotein-toxic payload molecule conjugate, the method for modulating growth of a cell population and a method of treating tumour cells.Type: ApplicationFiled: May 2, 2014Publication date: April 21, 2016Inventors: Tero SATOMAA, Jari HELIN, Filip S. EKHOLM
-
Patent number: 9260535Abstract: Objective of the present invention is to provide polysaccharides which modulate immune response, and which can be used as ingredients in edible products or pharmaceutical compositions. The present invention provides such polysaccharides obtained from the species Camellia sinensis, which comprise a rhamnogalacturonan-I core, and wherein the molar ratio of galacturonyl acid residues to rhamnosyl residues in the backbone of the polysaccharide is close to 1:1. The present invention also provides edible products or pharmaceutical compositions containing such polysaccharides, in order to modulate immune response.Type: GrantFiled: November 16, 2010Date of Patent: February 16, 2016Assignee: NutriLeads B.V.Inventors: Ruud Albers, Jari Helin, Werner Klaffke, Jean Hypolites Koek, Petronella Anna Kreijveld, Jari Natunen, Erwin Werner Tareilus, Richardus Paulus Anton Oranje
-
Publication number: 20150314007Abstract: The invention relates to novel linker-payload molecule conjugates. The invention also relates to novel cell binder-linker-payload molecule conjugates, in particular antibody conjugates of dolastatin or auristatin derivatives.Type: ApplicationFiled: December 20, 2013Publication date: November 5, 2015Applicant: Glykos Finland OyInventors: Tero SATOMAA, Jari HELIN, Filip S. EKHOLM, Henna PYNNÖNEN
-
Publication number: 20150140576Abstract: The present invention describes glycans, which are specifically expressed by certain cancer cells, tumours and other malignant tissues. The present invention describes methods to detect cancer specific glycans as well as methods for the production of reagents binding to said glycans. The invention is also directed to the use of said glycans and reagents binding to them for the diagnostics of cancer and malignancies. Furthermore, the invention is directed to the use of said glycans and reagents binding to them for the treatment of cancer and malignancies. Moreover, the present invention comprises efficient methods to differentiate between malignant and benign tumors by analyzing glycan structures.Type: ApplicationFiled: October 24, 2014Publication date: May 21, 2015Applicant: GLYKOS FINLAND OYInventors: Tero SATOMAA, Jari NATUNEN, Annamari HEISKANEN, Anne OLONEN, Juhani SAARINEN, Noora SALOVUORI, Jari HELIN
-
Publication number: 20140056946Abstract: The invention relates to a method for production of a preparation from a vegetable material, said preparation being enriched in a polysaccharide with a backbone comprising rhamnogalacturonan-I cores, said method comprising the steps: mixing the vegetable material with a polar alcoholic solvent; and separating a solid residue obtained in step a) from the solvent; and mixing the solid residue obtained in step b) with a buffered aqueous solution having a pH between 7 and 8. Also provided is a preparation containing rhamnogalacturonan-I pectins that can be obtained by this method and the use of such a preparation to modulate immune response.Type: ApplicationFiled: April 27, 2012Publication date: February 27, 2014Inventors: Jari Helin, Jean Hypolites Koek
-
Patent number: 8546353Abstract: The present invention relates to a combination of a hyaluronan oligomer and/or polymer and a factor capable of mobilizing stem cells. The present invention also relates to a method for altering the relative amounts of blood cells and/or the types of blood cells in a subject by administering the combination to the subject. Further, the present invention relates to a method for mobilizing stem cells to the bloodstream of a subject by administering the combination to the subject. Additionally, the present invention relates to a hyaluronan oligomer and/or polymer.Type: GrantFiled: May 6, 2011Date of Patent: October 1, 2013Assignee: Glykos Finland OyInventors: Johanna Nystedt, Heidi Anderson, Tero Satomaa, Jari Natunen, Jari Helin, Juhani Saarinen
-
Publication number: 20130064858Abstract: Objective of the present invention is to provide polysaccharides which modulate immune response, and which can be used as ingredients in edible products or pharmaceutical compositions. The present invention provides such polysaccharides obtained from the species Camellia sinensis, which comprise a rhamnogalacturonan-I core, and wherein the molar ratio of galacturonyl acid residues to rhamnosyl residues in the backbone of the polysaccharide is close to 1:1. The present invention also provides edible products or pharmaceutical compositions containing such polysaccharides, in order to modulate immune response.Type: ApplicationFiled: November 16, 2010Publication date: March 14, 2013Inventors: Ruud Albers, Jari Helin, Werner Klaffke, Jean Hypolites Koek, Petronella Anna Kreijveld, Jari Natunen, Erwin Werner Tareilus, Richardus Paulus Anton Oranje
-
Patent number: 8313912Abstract: The invention concerns a method for diagnosing cancer in a biological sample by determining the presence of a LacdiNAc oligosaccharide sequence. The invention can be used for diagnostic agents, pharmaceutical compositions, cancer vaccines, and antigenic carbohydrate substances. The presence of cancer and malignancies is determined by contacting the biological sample with a reagent that binds to the oligosaccharide sequence. This same method can also be used in the treatment of cancer and malignancies.Type: GrantFiled: August 16, 2002Date of Patent: November 20, 2012Assignee: Glykos Finland OyInventors: Juhani Saarinen, Jari Helin, Tero Satomaa
-
Publication number: 20110274646Abstract: The present invention relates to a combination of a hyaluronan oligomer and/or polymer and a factor capable of mobilizing stem cells. The present invention also relates to a method for altering the relative amounts of blood cells and/or the types of blood cells in a subject by administering the combination to the subject. Further, the present invention relates to a method for mobilizing stem cells to the bloodstream of a subject by administering the combination to the subject. Additionally, the present invention relates to a hyaluronan oligomer and/or polymer.Type: ApplicationFiled: May 6, 2011Publication date: November 10, 2011Applicants: Glykos Finland Oy, Suomen Punainen Risti VeripalveluInventors: Johanna Nystedt, Heidi Anderson, Tero Satomaa, Jari Natunen, Jari Helin, Juhani Saarinen
-
Publication number: 20110250235Abstract: The present invention is directed to a method of production of an immunostimulatory composition having a saccharide fraction, the method including the steps of hydrolyses of yeast cells and recovering the soluble fraction. The saccharide fraction having composition thus obtained may be incorporated as a food or beverage component or be used as a pharmaceutical for treatment of specific conditions.Type: ApplicationFiled: December 18, 2009Publication date: October 13, 2011Applicant: GLYKOS FINLAND OYInventors: Juhani Saarinen, Ritva Niemela, Jari Helin, Jari Natunen, Jukka Hiltunen
-
Publication number: 20110191867Abstract: The invention provides peptide epitopes for use in the prevention and/or treatment of influenza or for the development of such treatment or vaccine against influenza. The invention also relates to a method for evaluating the potential of a chemical entity, such as an antibody, to bind to a peptide epitope derived from the divalent sialoside binding site of hemagglutinin protein of influenza virus, and to conjugates containing one or more such peptide epitopes. The peptide epitopes of the invention are cyclic peptides comprising a 7-mer peptide derived from H1, H3 or H5 hemagglutinin of influenza virus. The 7-mer peptide has a sequence corresponding to the loop sequence at positions 220-226 of X31-hemagglutinin.Type: ApplicationFiled: October 24, 2008Publication date: August 4, 2011Applicant: GLYKOS FINLAND OYInventors: Jari Natunen, Jukka Hiltunen, Ritva Niemela, Jari Helin, Olli Aitio
-
Publication number: 20110009613Abstract: The invention relates to a method of degrading plant-based ?-glucan into a controlled molecular size by hydrolyzing ?-glucan in a closed space under pressure by means of an acid at an elevated temperature. The invention also relates to a degraded ?-glucan product. The ?-glucan product obtained is useful in foodstuffs applications, such as beverages.Type: ApplicationFiled: December 18, 2008Publication date: January 13, 2011Applicant: Valtion Teknillinen TutkimuskeskusInventors: Anu Kaukovirta-Norja, Pekka Lehtinen, Ilkka Virkajärvi, Mikko Suortti, Olavi Myllymäki, Jari Helin, Anne Olonen
-
Publication number: 20100184150Abstract: The present invention is directed to a novel saccharide composition isolated from a yeast culture. The invention is also directed to yeast cell based saccharide composition with increased water-solubility. The saccharide compositions disclosed in the invention can be used as nutritional or pharmaceutical additives or as part of nutritional or pharmaceutical composition in order to promote the health of an animal or human subject to which said composition is administered. The invention is also directed to methods of producing said saccharide compositions.Type: ApplicationFiled: June 13, 2008Publication date: July 22, 2010Applicants: GLYKOS FINLAND OY, SUOMEN REHU OYInventors: Ritva Niemela, Juhani Saarinen, Jari Helin, Janica Wakkinen
-
Publication number: 20100093659Abstract: The present invention is directed to conjugates for biorecognition comprising (i) an carbohydrate backbone structure (PO) of 5 to 20 monosaccharide units, (ii) oligosaccharide biorecognition groups (Bio) of 1 to 10 monomer units, (iii) a bifunctional spacer groups of the formula -(y)p-(S)q-(z)r-, wherein S is a spacer group, p, q and r are each 0 or 1, whereby at least one of p and r is different from 0, and y and z are chemoselective ligation groups, which covalently link a said Bio group to said backbone structure, and the degree of conjugation, indicating the average number of covalently attached Bio biorecognition groups per monomer unit of the backbone, being from 0.2 to 1. The invention is also directed to processes for their preparation, intermediates for use in the process as well as use of said conjugates, especially for inhibiting pathogenic bacteria.Type: ApplicationFiled: December 13, 2007Publication date: April 15, 2010Applicant: GLYKOS FINLAND OYInventors: Jari Natunen, Jari Helin, Krista Weikkolainen
-
Publication number: 20100074920Abstract: The invention relates to the method for evaluating the potential of a chemical entity, such as an antibody, to bind to a peptide epitope derived from the divalent sialoside binding site of hemagglutinin protein of influenza virus. The invention also provides peptide epitopes 5 for use in the prevention and/or treatment of influenza or for the development of such treatment or vaccine against influenza.Type: ApplicationFiled: October 26, 2007Publication date: March 25, 2010Applicant: GLYKOS FINLAND OYInventors: Jari Natunen, Jukka Hiltunen, Ritva Niemela, Jari Helin, Olli Aitio